Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if
phenylbutyrate can increase the removal of alpha-synuclein from the brain into the
bloodstream. Alpha-synuclein forms abnormal protein deposits in dopamine neurons and is
believed to cause the death of brain cells, leading to Parkinson's Disease.